Structure Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
GPCR$21.41+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Trading Arrangements
During the three months ended December 31, 2023, the following officer (as defined in Rule 16a-1(f) under the Exchange Act) adopted a “Rule 10b5-1 trading arrangement” (as such term is defined in Item 408(a) of Regulation S-K).
| | ||||||
|---|---|---|---|---|---|---|
| · · · Type of Trading Arrangement · · | ||||||
| Name and Position | Action | Date | Rule 10b5-1* | Non-Rule 10b5-1** | Total ADSs to be Sold | Expiration Date |
| Xichen Lin, Ph.D., Chief Scientific Officer | Adoption | December 28, 2023 | X | | 106,666 | December 15, 2024 |
| | | | | | | |
| * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. | ||||||
| ** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.